Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) has been given a $3.00 target price by analysts at Maxim Group in a report issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective would indicate a potential upside of 380.08% from the company’s previous close.

Other equities analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Roth Capital restated a “buy” rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd.

Shares of Actinium Pharmaceuticals (NYSEMKT:ATNM) traded down 0.2400% during mid-day trading on Wednesday, reaching $0.6234. The company’s stock had a trading volume of 585,931 shares. The firm’s market cap is $49.88 million. Actinium Pharmaceuticals has a 52-week low of $0.54 and a 52-week high of $1.72. The firm has a 50 day moving average price of $0.66 and a 200 day moving average price of $0.98.

ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals Inc (ATNM) PT Set at $3.00 by Maxim Group” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/01/actinium-pharmaceuticals-inc-atnm-pt-set-at-3-00-by-maxim-group.html.

A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. Vanguard Group Inc. grew its holdings in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) by 7.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,143,745 shares of the biotechnology company’s stock after purchasing an additional 148,579 shares during the period. Vanguard Group Inc. owned approximately 3.67% of Actinium Pharmaceuticals worth $2,616,000 as of its most recent SEC filing.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.